TC
RCKT icon

TFS Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

TFS Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,879
Closed -$223K – 867
2016
Q3 		$223K Sell
5,879
-8,355
-59% -$263K 0.05% 515
2016
Q2 		$424K Buy
+14,234
New +$500K 0.08% 421
2015
Q4 		– Sell
-8,141
Closed -$306K – 872
2015
Q3 		$306K Buy
+8,141
New +$374K 0.03% 662

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

TFS Capital's RCKT Position: Q4 2016 in Review

TFS Capital sold out of Rocket Pharmaceuticals (RCKT) in Q4 2016, closing a stake of 5,879 shares — an estimated $223K sold.

TFS Capital first reported a position in RCKT in Q3 2015 and held it in 3 quarters. The position peaked at $424K in Q2 2016. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

  • TFS Capital reported no remaining Rocket Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 5,879 Rocket Pharmaceuticals shares in Q4 2016, an estimated $223K.
  • TFS Capital first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • TFS Capital's Rocket Pharmaceuticals position peaked at $424K in Q2 2016.
  • 82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.